TEVA
Teva Pharmaceutical Industries Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$41.96
+0.26%Nov 4, 2026, 16:40 UTC
Teva shares rose after the company’s third-quarter earnings beat estimates and its 2026 revenue outlook was raised.
Source:Nov 4, 2026, 13:01 UTC
MindWalk Holdings announced a multi-year agreement with Teva Pharmaceuticals Australia to deploy ReefIQ and specified LensAI capabilities for defined antibody-discovery work.
Source:Nov 3, 2026, 12:29 UTC
Teva Pharmaceutical reported a third-quarter profit gain that beat estimates.
Source:Nov 3, 2026, 12:07 UTC
TEVA PHARMACEUTICAL INDUSTRIES LTD reported third-quarter revenue of $4.4 billion, above the market estimate of $4.24 billion.
Source:Nov 2, 2026, 15:01 UTC
TEVA PHARMACEUTICAL INDUSTRIES LTD will discontinue its Phase 2 TOPAS-MSA study evaluating emrusolmin in adults with multiple system atrophy.
Source:Nov 2, 2026, 13:02 UTC
TEVA PHARMACEUTICAL INDUSTRIES LTD stopped a Phase II study.
Source:Nov 2, 2026, 13:02 UTC
TEVA PHARMACEUTICAL INDUSTRIES LTD shares fell 5.4%.
Source:Oct 30, 2026, 21:58 UTC
BioXcel Therapeutics and its subsidiaries sold substantially all of their neuroscience assets, including rights to IGALMI and BXCL501, to TEVA PHARMACEUTICAL INDUSTRIES LTD for $57.5 million upfront, with potential development and commercial milestone payments.
Oct 29, 2026, 21:59 UTC
TEVA PHARMACEUTICAL INDUSTRIES LTD announced that Dr. David J. Brailer was elected to its board of directors, effective November 3, 2026.
Oct 27, 2026, 12:00 UTC
Teva acquired worldwide rights to BXCL501, a potential at-home treatment for agitation under FDA review.
Source:Oct 12, 2026, 21:45 UTC
TEVA PHARMACEUTICAL INDUSTRIES LTD announced that it will host an R&D Day in New York City on November 11, 2026.
Oct 12, 2026, 17:10 UTC
Teva expects to launch Weltruza in the United States soon.
Source:Oct 10, 2026, 19:00 UTC
Teva shares closed 2% higher in Tel Aviv and MedinCell SA shares rose 16.9% in Paris.
Source:Oct 9, 2026, 11:00 UTC
The U.S. Food and Drug Administration approved Teva’s WELTRUZA (olanzapine) extended-release injectable suspension for adults with schizophrenia.
Oct 9, 2026, 05:45 UTC
The Royal College of Pharmacy ended TEVA PHARMACEUTICAL INDUSTRIES LTD’s sponsorship and exhibition arrangement for its forthcoming annual conference, part of a £15,000 deal covering four events.
Source:Oct 3, 2026, 14:45 UTC
A Russian air strike on Friday, Oct. 2 set fire to a pharmaceutical storage warehouse belonging to Ukrainian drug distributor Venta near Kyiv, destroying inventories of medicines made by Bayer, Sanofi, Pfizer, Teva, Darnytsia and Farmak.
Source:Oct 2, 2026, 12:00 UTC
Teva Pharmaceuticals presented new efficacy and safety data for ecopipam, an investigational treatment for pediatric Tourette syndrome, at the International Congress of Parkinson's Disease and Movement Disorders in Seoul, South Korea.
Oct 2, 2026, 06:30 UTC
The Royal College of Nursing ended its commercial partnership with Teva UK and dropped the firm as sponsor of its 30 October 2026 migraine and headache services event in London.
Sep 28, 2026, 20:00 UTC
The U.S. FDA approved Teva Pharmaceutical Industries' DEGEVMA (denosumab-adet), a biosimilar to Xgeva, for preventing bone complications in advanced cancer, treating giant cell tumor of bone, and treating hypercalcemia of malignancy.
Source:Sep 23, 2026, 20:45 UTC
Teva Pharmaceutical Industries announced it will release its third quarter 2026 financial results and host a conference call on November 3, 2026.
Source:Sep 19, 2026, 11:00 UTC
The Delhi High Court ruled that a ₹1,851 crore payment made by Ranbaxy Laboratories to Teva Israel under a settlement agreement is not taxable in India, allowing Teva Israel's refund subject to guarantees.
Source:Sep 18, 2026, 20:32 UTC
Teva Pharmaceuticals announced new data from a discrete choice experiment on healthcare provider treatment preferences for VMAT2 inhibitors in tardive dyskinesia in older patients, presented at Psych Congress in New Orleans.
Source:Sep 18, 2026, 20:30 UTC
Teva Pharmaceuticals presented new post hoc data from the pivotal SOLARIS Phase 3 trial for olanzapine LAI (TEV-'749), a once-monthly subcutaneous long-acting injectable for treating schizophrenia in adults, at Psych Congress in New Orleans.
Source:Sep 15, 2026, 12:49 UTC
Teva Pharmaceutical Industries Ltd. completed a major debt refinancing.
Source:Sep 14, 2026, 21:52 UTC
Teva Pharmaceuticals moved its shares from American Depositary Receipts to direct trading on the New York Stock Exchange.
Source:Sep 14, 2026, 12:03 UTC
Teva Pharmaceutical Industries began trading its ordinary shares directly on the New York Stock Exchange, marking a milestone in its pivot to growth strategy.
Page 1Next →